Abstract: Described herein are methods for purifying I?Ip from a biological material using an endotoxin-binding agent. The method involves applying the biological material containing the I?Ip to an endotoxin-binding agent, discarding the flow through, applying a wash buffer(s), and eluting the I?Ip from the endotoxin-binding agent.

Abstract: The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-alpha inhibitor proteins (I?Ips), including, e.g., inter-alpha inhibitor (I?I) and/or pre-alpha inhibitor (P?I).

Abstract: Described herein are methods for quantifying IAIP levels in a sample.

Abstract: Described herein are methods for quantifying IAIP levels in a sample.

Abstract: Featured are a foodstuff containing an inter-alpha inhibitor protein (l?lp) (e.g., l?l, P?l, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof), methods of preparing a food-stuff containing an l?lp, and methods of treating and/or reducing the likelihood of developing a disease or condition (e.g., a disease or condition characterized by inflammation and/or low levels of an l?lp) in a subject in need thereof by administering a composition or a foodstuff containing an l?lp. Also featured are methods of purifying an l?lp (e.g., l?l, P?l, a heavy chain (e.g., H1, H2, H3, H4, and/or H5), a light chain (e.g., bikunin), or a combination thereof) from milk.

Abstract: Described herein are methods for quantifying lAIP levels in a sample (e.g., from a subject) using lAIP ligand-based assays. Also disclosed are methods for measuring lAIP-IAIP ligand complexes, and methods of evaluating, monitoring, and treating subjects using the aforementioned lAIP quantification methods.

Abstract: The invention features methods for treating or preventing pulmonary diseases, including acute respiratory distress syndrome (ARDS) and pneumonia, in a subject in need thereof that involve administering to the subject inter-alpha inhibitor proteins (lalps), including, e.g., inter-alpha inhibitor (lal) and/or pre-alpha inhibitor (Pal).

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (l?lp). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.

Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.

Abstract: The invention relates to methods of treatment of medical conditions (e.g., diseases and injuries) in a mammal (e.g., a human), such as hypoxia/ischemia, burns, and viral infections (e.g., influenza, West Nile virus, and Dengue fever), in adults and in children (e.g., neonates) by administering a composition that includes an IAIP.

Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (I?Ip). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.

Abstract: It is disclosed herein that blockade of inter-alpha-trypsin inhibitor (IaI) prevents the development of airway hyperresponsiveness in animal models of asthma and chronic obstructive pulmonary disease. Provided herein are methods of treating an airway disease or disorder in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. Also provided is a method of preventing or reducing airway hyperresponsiveness in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. The IaI inhibitor can be any compound that inhibits the expression or activity of IaI or a gene encoding an IaI polypeptide. In some embodiments, the IaI inhibitor is administered locally to the airway of the subject in need of treatment. For example, the inhibitor can be administered by aerosol delivery, such as by using an inhaler or nebulizer.

Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.